Acoustic and hearing-perceptual voice analysis in individuals with idiopathic Parkinson's disease in "on" and "off" stages;Análise acústica e perceptivo-auditiva da voz em indivíduos com doença de parkinson idiopática nos estágios "on" e "off"

Arquivos de Neuro-Psiquiatria

Volumn 68, Issue 5, 2010, Pages 706-711

  Santos, Luiza Lara M ^a   dos Reis, Larissa Oliveira ^b   Bassi, Iara ^b   Guzella, Clara ^b   Cardoso, Francis ^c   Reis, César ^d   Gama, Ana Cristina Côrtes ^e  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Speech and Language Therapist Voluntary   (Brazil)

^c UFMG   (Brazil)

^d Phonetics Laboratory Coordinating Teacher Associate   (Brazil)

^e FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Hearing perception; Parkinson's disease; Speech acoustics; Voice

Indexed keywords

ACOUSTICS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GRBASI SCALE; HEARING; HUMAN; IDIOPATHIC DISEASE; MALE; NOISE; PARKINSON DISEASE; RATING SCALE; SPEECH; VOICE;

EID: 78649498829     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/s0004-282x2010000500006     Document Type: Article

References (30)

1. Shih MC, Hoexter MQ, Andrade LAF, Bressan RA. Doença de Parkinson e neu roimagem do transportador de dopamina: uma revisão crítica. São Paulo Med J 2006;124:168-175.
2. Cardoso F, Camargos ST, Silva JRGA. Etiologia de parkinsonismo em uma clíni ca brasileira de distúrbios do movimento. Arq Neuropsiquiatr 1998;56:171-175.
3. Azevedo LL, Cardoso F, Reis C. Análise acústica da prosódia em mulheres com doença de Parkinson: efeito da Levodopa. Arq Neuropsiquiatr 2003;61:995-998.
4. Gallena S, Smith PJ, Zeffiro T, Ludlow CL. Effects of levodopa on larynge al muscle activity for voice onset and offset in Parkinson disease. J Speech Lang Hear Res 2001;44:1284-1299.
5. Nicaretta DH, Pereira JS, Pimentel MLV. Distúrbios autonômicos na doença de Parkinson. Rev Assoc Med Bras 1998;44:120-122.
6. Teixeira AL Jr, Cardoso F. Tratamento inicial da doença de Parkinson. Rev Neurociências 2004;12:146-151.
7. Marsden CD. Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57: 672-681.
8. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458.
9. Behlau M, Organizadora. Voz: o livro do especialista Vol 1. Rio de Janeiro: Re vinter; 2001;1:96-100;130-164.
10. Hirano M. Clinical examination of voice. New York: Springer Verlag, 1981.
11. Dejonckere PH, Remacle M, Fresnel-Elbaz E, Woisard V, Crevier-Buchman L, Millet B. Differentiated perceptual evaluation of pathological voice quality: reliability and correlations with acoustic measurements. Rev Laryngol Otol Rhinol 1996;117:219-224.
12. Sanabria J, Ruiz PG, Gutierrez R, et al. The effect of levodopa on vocal func tions in Parkinson's disease. Clin Neuropharmacol 2001;24:99-102.
13. Gamboa J, Jimênez-Jimênez FJ, Nieto A, et al. Acoustic voice analysis in pa tients with Parkinson's disease treated with dopaminergic drugs. J Voice 1997;11:314-320.
14. Mourão LF, Aguiar PMC, Ferraz FAP, Behlau MS, Ferraz HB. Acoustic voice as sessment in Parkinson's disease patients submitted to posteroventral pallidotomy. Arq Neuropsiquiatr 2005;63:20-25.
15. Goberman AM, Blomgren M. Fundamental frequency change during off set and onset of voicing in individuals with parkinsin's disease. J Voice 2008; 22:178-191.
16. Carrilo L, Ortiz KZ. Análise vocal (auditiva e acústica) nas disartrias. Pró-Fono R Atual Cient 2007;19:381-386.
17. Ho AK, Bradshaw JL, Iansek R. For better or worse: the effect of levodopa on speech in Parkinson's disease. Mov Disord 2008;23:574-580.
18. Baumgartner CA, Sapir S, Ramig TO. Voice quality changes following phona tory-respiratory effort treatment (LSVT) versus respiratory effort treatment for individuals with Parkinson disease. J Voice 2001;15:105-114.
19. Gasparini G, Diaféria G, Behlau M. Queixa vocal e análise perceptiva-auditiva de pacientes com doença de Parkinson. R Ci Méd Biol (Salvador) 2003;2:72-76.
20. Carrara de Angelis E. Deglutição, configuração laríngea, análise clínica e acús tica computadorizada da voz de pacientes com doença de Parkinson. Tese. São Paulo:Universidade Federal de São Paulo - EPM. 2000.
21. Countryman S, Ramig LO, Pawlas AA. Speech and voice déficits in Parkin sonian plus syndromes: can they be treated? NCVS Status and Progress Report 1996;6:99-111.
22. Behlau M. Voz: o livro do especialista. Vol. II. Rio de Janeiro: Revinter 2005: 122-129.
23. De Letter M, Santens P, De Bodt M, Van MG, Van BJ, Boon P. The effect of levodopa on respiration and word intelligibility in people with advanced Parkinson's disease. Clin Neurol Neurosurgery 2007;109:495-500.
24. Cioni M, Richards CL, Malouin F, Bedard PJ, Lemieux R. Characteristics of the electromyographic patterns of lower limb muscles during gait in patients with Parkinson's disease when off and on L-Dopa treatment. Ital J Neurol Sci 1997;18:195-208.
25. Quagliato LB, Viana MA, Quagliato EMAB, Simis S. Alterações do olfato na doença de Parkinson. Arq Neuropsiquiatr 2007;65:647-652.
26. Deems DA, Kaplan P, Schiumaker J, Doty RL. Studies of oflactory function in parkinson's patients receiving electrotherapy for control of extrapyramidal symptoms. Chem Senses 2001;26: 1115.
27. Cools R, Stefanova E, Barker RA, Robbins TW, Owen AM. Dopaminergic mod ulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed. PET Brain 2002;125:584-594.
28. Lange KW, Robbins TW, Marsden CD, James M, Owen AM, Paul GM. L-do pa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology (Berl) 1992; 107:394-404.
29. Costa A, Peppe A, Brusa L, Caltagirone C, Gatto I, Carlesimo GA. Levodopa improves time-based prospective memory in Parkinson's disease. J Internat Neuropsychol Soc 2008;14: 601-610.
30. Erdal KJ. Depression and anxiety in persons with parkinson's disease with and without "on-off" phenomena. J Clin Psychol Med Settings 2001;8:293-299.